Comparing signaling networks between normal and transformed hepatocytes using discrete logical models.

Substantial effort in recent years has been devoted to constructing and analyzing large-scale gene and protein networks on the basis of "omic" data and literature mining. These interaction graphs provide valuable insight into the topologies of complex biological networks but are rarely context specific and cannot be used to predict the responses of cell signaling proteins to specific ligands or drugs. Conversely, traditional approaches to analyzing cell signaling are narrow in scope and cannot easily make use of network-level data. Here, we combine network analysis and functional experimentation by using a hybrid approach in which graphs are converted into simple mathematical models that can be trained against biochemical data. Specifically, we created Boolean logic models of immediate-early signaling in liver cells by training a literature-based prior knowledge network against biochemical data obtained from primary human hepatocytes and 4 hepatocellular carcinoma cell lines exposed to combinations of cytokines and small-molecule kinase inhibitors. Distinct families of models were recovered for each cell type, and these families clustered topologically into normal and diseased sets.

[1]  Steffen Klamt,et al.  Visual setup of logical models of signaling and regulatory networks with ProMoT , 2006, BMC Bioinformatics.

[2]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[3]  Takashi Kumada,et al.  Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma. , 2005, Biochemical and biophysical research communications.

[4]  T. Fujii,et al.  Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. , 2008, Cancer research.

[5]  Goldberg,et al.  Genetic algorithms , 1993, Robust Control Systems with Genetic Algorithms.

[6]  Ioannis Xenarios,et al.  A method for the generation of standardized qualitative dynamical systems of regulatory networks , 2005, Theoretical Biology and Medical Modelling.

[7]  N. D. Clarke,et al.  Towards a Rigorous Assessment of Systems Biology Models: The DREAM3 Challenges , 2010, PloS one.

[8]  Aviv Regev,et al.  Transcriptional Regulatory Circuits: Predicting Numbers from Alphabets , 2009, Science.

[9]  M. Vidal,et al.  Interactome: gateway into systems biology. , 2005, Human molecular genetics.

[10]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[11]  S. Thorgeirsson,et al.  Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer , 2002, Hepatology.

[12]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[13]  M. Vidal,et al.  Literature-curated protein interaction , 2009 .

[14]  A. Bauer-Mehren,et al.  Pathway databases and tools for their exploitation: benefits, current limitations and challenges , 2009, Molecular systems biology.

[15]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[16]  Julio Saez-Rodriguez,et al.  Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling , 2007, PLoS Comput. Biol..

[17]  H. Hirt,et al.  Protein networking: insights into global functional organization of proteomes , 2008, Proteomics.

[18]  Wei Keat Lim,et al.  The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.

[19]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[20]  Gavin Harper,et al.  Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[21]  Yves Van de Peer,et al.  Prediction of a gene regulatory network linked to prostate cancer from gene expression, microRNA and clinical data , 2010, Bioinform..

[22]  D. Lauffenburger,et al.  Networks Inferred from Biochemical Data Reveal Profound Differences in Toll-like Receptor and Inflammatory Signaling between Normal and Transformed Hepatocytes* , 2010, Molecular & Cellular Proteomics.

[23]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[24]  Robert Newton,et al.  Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. , 2005, American journal of respiratory and critical care medicine.

[25]  D. Lauffenburger,et al.  A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines*S , 2005, Molecular & Cellular Proteomics.

[26]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[27]  Ji Luo,et al.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. , 2010, Cancer research.

[28]  D. Lauffenburger,et al.  Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction , 2009, Molecular systems biology.

[29]  H. Lee,et al.  Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. , 2006, Gastroenterology.

[30]  M. Ozturk,et al.  Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells , 2009, Molecular Cancer.

[31]  J. Wands,et al.  Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development. , 2003, Gastroenterology.

[32]  M J Saad,et al.  Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. , 1992, The Journal of clinical investigation.

[33]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[34]  P. Cohen,et al.  GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.

[35]  David E. Goldberg,et al.  Genetic Algorithms in Search Optimization and Machine Learning , 1988 .

[36]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[37]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[38]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[39]  Steffen Klamt,et al.  Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling , 2009, BMC Systems Biology.

[40]  T. Jaakkola,et al.  Bayesian Network Approach to Cell Signaling Pathway Modeling , 2002, Science's STKE.

[41]  S. Giordano,et al.  From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.

[42]  Mona Singh,et al.  Toward the dynamic interactome: it's about time , 2010, Briefings Bioinform..

[43]  Julio Saez-Rodriguez,et al.  Flexible informatics for linking experimental data to mathematical models via DataRail , 2008, Bioinform..

[44]  M. Vidal,et al.  Literature-curated protein interaction datasets , 2009, Nature Methods.

[45]  Tony Pawson,et al.  Cell-Specific Information Processing in Segregating Populations of Eph Receptor Ephrin–Expressing Cells , 2009, Science.

[46]  R. Aebersold,et al.  Applying mass spectrometry-based proteomics to genetics, genomics and network biology , 2009, Nature Reviews Genetics.

[47]  D. Lauffenburger,et al.  Systems Analysis of EGF Receptor Signaling Dynamics with Micro-Western Arrays , 2010, Nature Methods.

[48]  N. D. Clarke,et al.  Correction: Towards a Rigorous Assessment of Systems Biology Models: The DREAM3 Challenges , 2010, PLoS ONE.

[49]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[50]  James F. Callahan,et al.  Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation , 2005, Journal of Pharmacology and Experimental Therapeutics.